About Jellagen
Jellagen is a company based in Pembroke Dock (United Kingdom) founded in 2013 by Alex Paul Muhlholzl. Jellagen has raised $21.28 million across 6 funding rounds from investors including Newable, Development Bank of Wales and Thai Union Group. The company has 13 employees as of December 31, 2020. Jellagen offers products and services including Collagen Type 0, Wound Repair Application, Bone Repair Application, Cartilage Repair Application, and Implantable Devices. Jellagen operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Pembroke Dock, United Kingdom
- Employees 13 as on 31 Dec, 2020
- Founders Alex Paul Muhlholzl
- SectorsHealthcare
- PhoneLocked
- WebsiteLocked
- SocialLocked
- Legal Name Jellagen Limited
- Date of Incorporation 29 May, 2013
- Jurisdiction STIRLING
- Annual RevenueNot available
- Net ProfitNot available
- EBITDANot available
- Total Equity Funding$21.28 M (USD)
in 6 rounds
- Latest Funding Round$10.6 M (USD), Series A
Dec 07, 2022
- InvestorsNewable
& 5 more
- Employee Count13
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Jellagen
Jellagen offers a comprehensive portfolio of products and services, including Collagen Type 0, Wound Repair Application, Bone Repair Application, Cartilage Repair Application, and Implantable Devices.
Collagen for advanced wound and tissue healing in medicine
Solution for healing wounds using collagen-based innovation
Collagen for bone regeneration in regenerative medicine
Biomaterial aiding cartilage repair and tissue engineering
Collagen-based devices for in-vivo medical applications
People of Jellagen
Unlock access to complete
Unlock access to complete
Funding Insights of Jellagen
Jellagen has successfully raised a total of $21.28M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $10.6 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jellagen
Jellagen has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Newable, Development Bank of Wales and Thai Union Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of equity funding and business & property development loans | Locked | Locked | Locked | |
Seafood products are distributed globally by Thai Union Group. | Locked | Locked | Locked | |
Partnership of councils fostering innovation, investment, and inclusive growth in South East Wales. | Locked | Locked | Locked |
Investor details for Jellagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jellagen
Investment portfolio details for Jellagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Jellagen
Detailed financials for Jellagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jellagen Comparisons
Peer comparison for Jellagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jellagen
Jellagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| Locked | Locked | Locked | Antibody-siRNA complexes are developed for cancer treatment. | |
| Locked | Locked | Locked | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| Locked | Locked | Locked | Yeast cells are genetically engineered to produce medicinal products. | |
| Locked | Locked | Locked | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| Locked | Locked | Locked | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Jellagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jellagen
Complete news archive for Jellagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jellagen
Jellagen was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Jellagen is headquartered in Pembroke Dock, United Kingdom. It is registered at Pembroke Dock, Pembrokeshire, United Kingdom.
Thomas-Paul Descamps is the current CEO of Jellagen.
Jellagen is a funded company, having raised a total of $21.28M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Jellagen is 13.
Provider of medical-grade collagen type for life science researchh. It offers Collagen Type 0 is a medical-grade collagen derived from jellyfish species, including Rhizostoma pulmo. It has applications in tissue engineering and regenerative medicine.
Jellagen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Jellagen offers Collagen Type 0, Wound Repair Application, Bone Repair Application, Cartilage Repair Application, and Implantable Devices.
Jellagen has 6 investors. Key investors include Newable, Development Bank of Wales, Thai Union Group, Cardiff Capital Region, and Development Bank of Wales.